{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:32Z","timestamp":1792013912816,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T00:00:00Z","timestamp":1490313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["intramural funding"],"award-info":[{"award-number":["intramural funding"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["1K23AR068440-01"],"award-info":[{"award-number":["1K23AR068440-01"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1222-3","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T03:34:53Z","timestamp":1490326493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study"],"prefix":"10.1186","volume":"19","author":[{"given":"Peter C.","family":"Grayson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Merideth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Nida","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Novakovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Joyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaela","family":"Goldbach-Mansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailin H.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,24]]},"reference":[{"issue":"12","key":"1222_CR1","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67(12):1656\u201362.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1222_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet\u2019s disease. Autoimmun Rev. 2015;14(1):1\u20139.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1222_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet\u2019s disease: a case series. Dermatology. 2014;228(3):211\u20134.","journal-title":"Dermatology"},{"issue":"5","key":"1222_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281\u20136.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"1222_CR5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol. 2015;34(7):1293\u2013301.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1222_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A Gul","year":"2012","unstructured":"Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563\u20136.","journal-title":"Ann Rheum Dis"},{"key":"1222_CR7","doi-asserted-by":"crossref","unstructured":"Sibley CH, Plass N, Snow J, Wiggs E, Brewer C, King K, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease (NOMID) treated with anakinra. Arthritis Rheum. 2012;64(7):2375-86.","DOI":"10.1002\/art.34409"},{"issue":"Suppl 9","key":"1222_CR8","first-page":"854","volume":"58","author":"C Forbess","year":"2008","unstructured":"Forbess C, Swearingen C, Yazici Y. Beh\u00e7et\u2019s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with the Beh\u00e7et\u2019s Disease Current Activity Form (BDCAF). Arthritis Rheum. 2008;58 Suppl 9:854.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1222_CR9","first-page":"931","volume":"31","author":"G Gilworth","year":"2004","unstructured":"Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: a quality of life measure specific to Behcet\u2019s disease. J Rheumatol. 2004;31(5):931\u20137.","journal-title":"J Rheumatol"},{"issue":"8","key":"1222_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bhakta","year":"1999","unstructured":"Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Beh\u00e7et\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology. 1999;38(8):728\u201333.","journal-title":"Rheumatology"},{"issue":"10","key":"1222_CR11","first-page":"1428","volume":"17","author":"K Hamzaoui","year":"1990","unstructured":"Hamzaoui K, Hamza M, Ayed K. Production of TNF-alpha and IL-1 in active Behcet\u2019s disease. J Rheumatol. 1990;17(10):1428\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"1222_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s00296-005-0040-0","volume":"26","author":"S Pay","year":"2006","unstructured":"Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behcet\u2019s disease. Does interleukin-1 beta play a major role in Behcet\u2019s synovitis? Rheumatol Int. 2006;26(7):608\u201313.","journal-title":"Rheumatol Int"},{"issue":"8","key":"1222_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet\u2019s disease. Nat Genet. 2010;42(8):698\u2013702.","journal-title":"Nat Genet"},{"issue":"16","key":"1222_CR14","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Turgut Ozturk B, Mat C, et al. Apremilast for Behcet\u2019s syndrome\u2013a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"1222_CR15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet\u2019s syndrome. N Engl J Med. 1990;322(5):281\u20135.","journal-title":"N Engl J Med"},{"issue":"12","key":"1222_CR16","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.3899\/jrheum.141147","volume":"42","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V, et al. Current Status, goals, and research agenda for outcome measures development in Behcet Syndrome: report from OMERACT 2014. J Rheumatol. 2015;42(12):2436\u201341.","journal-title":"J Rheumatol"},{"issue":"1","key":"1222_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.25057","volume":"62","author":"B Neven","year":"2010","unstructured":"Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease\/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258\u201367.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-017-1222-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:47:54Z","timestamp":1589550474000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1222-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,24]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1222-3","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,24]]},"assertion":[{"value":"17 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"69"}}